Maravai LifeSciences Holdings, Inc. (MRVI) Guidance & Earnings Results
On 2026-08-06 Maravai LifeSciences Holdings, Inc. raised guidance: "Adjusted EBITDA guidance raised from $30M-$32M to…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MRVIMaravai LifeSciences Holdings, Inc.Follow MRVI — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Raised | Adjusted EBITDA guidance raised from $30M-$32M to $33M-$35M · full year |
| 7 May 26 | Raised | Revenue guidance raised from $200-210M to $205-215M; Adjusted EBITDA guidance raised from $18-20M to $30-32M · full year |
| 25 Feb 26 | Raised | FY2026 revenue $200-210M vs FY2025 $185.7M; Adj EBITDA $18-20M vs FY2025 $(31.2)M · full year |
| 6 Nov 25 | Lowered | FY2025 revenue ~$185.0M · full year |
| 11 Aug 25 | Lowered | FY2025 revenue guidance withdrawn and suspended; targeting >$50M annualized cost savings; expects positive Adj. EBITDA and FCF by H2 2026 · full year |
Maravai LifeSciences Holdings, Inc. — questions
- What guidance did Maravai LifeSciences Holdings, Inc. give?
- On 2026-08-06: "Adjusted EBITDA guidance raised from $30M-$32M to $33M-$35M"
- When does Maravai LifeSciences Holdings, Inc. report earnings?
- Maravai LifeSciences Holdings, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Maravai LifeSciences Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.